NEW ATAI-Logo_Primary.png
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
July 07, 2021 19:47 ET | atai Life Sciences
BERLIN, Germany, July 07, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds...
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces Pricing of Upsized Initial Public Offering
June 17, 2021 23:21 ET | atai Life Sciences
BERLIN, June 17, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders,...
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces Launch of Initial Public Offering
June 11, 2021 07:59 ET | atai Life Sciences
BERLIN, June 11, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences B.V. (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the...